TENX Stock Forecast: Tenax Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.25
−10.07% on the day

The median 12-month analyst price target for Tenax Therapeutics, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$63.3M
Ticker Nerd rank
24/ 100
Median analyst target
$5.00
Analysts covering
10
Revenue$0.0
Operating income−$18.8M
Net income−$17.8M
Free cash flow−$14.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.8%
1M
−23.3%
YTD
−89.7%
1Y
−83.8%
From 52W high
−93.2%
From 52W low
0.0%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tenax Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
63
Quality
49
Accruals
46
Volatility
44
Growth
21
Issuance
20
Value
15
Momentum
15

Revisions (63): Analysts have, on balance, been raising their forecasts.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TENX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TENX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26TENXHigh $35.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
6
Buy
4
Hold
0
Sell
$4.00
Low
$5.00
Median
$35.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
31 Aug 2026GuggenheimDowngradeNeutral—
11 Aug 2026Canaccord GenuityMaintainsBuy$35 → $4.00
11 Aug 2026Chardan CapitalDowngradeNeutral$27 → $5.00
11 Aug 2026Evercore ISI GroupDowngradeIn-Line$39 → $5.00
11 Aug 2026GuggenheimMaintainsBuy$40 → $4.00
10 Aug 2026William BlairDowngradeMarket Perform—
31 July 2026Chardan CapitalMaintainsBuy$27
29 July 2026Cantor FitzgeraldReiteratesOverweight$35
28 July 2026Canaccord GenuityInitiatesBuy$35
22 July 2026Evercore ISI GroupInitiatesOutperform$39
2 July 2026Chardan CapitalMaintainsBuy$27
24 June 2026Cantor FitzgeraldReiteratesOverweight—
22 June 2026Chardan CapitalInitiatesBuy—
22 June 2026GuggenheimMaintainsBuy—
12 June 2026Piper SandlerMaintainsOverweight—
17 Mar 2026Cantor FitzgeraldInitiatesOverweight—
16 Mar 2026GuggenheimMaintainsBuy—
17 Dec 2025GuggenheimMaintainsBuy—
8 Sept 2025Piper SandlerInitiatesOverweight—
14 Aug 2025GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TENX.

Market Radar

This page is one stock. Monday covers all of them.

TENX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TENX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Tenax Therapeutics, Inc. returned −83.8% against +6.9% for the S&P 500, dividends included.

TENX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Jan 26Apr 26Jul 26Oct 26TENXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TENX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−64.2%

Higher than 18% of US stocks

Return on assets
−39.5%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tenax Therapeutics, Inc. has a market value of $63.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$64.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M.

  • Shares outstanding: 26.5M.

  • Tenax Therapeutics, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TENX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TENXTenax Therapeutics, Inc.$63.3M24
IBIOiBio, Inc.$56.4M32
NRXSNeurAxis, Inc.$58.3M47
CGTXCognition Therapeutics, Inc.$55.4M47
CHRSCoherus Oncology, Inc.$55.3M38
AZRAzora Therapeutics, Inc.$55.0M16
OKYOOKYO Pharma Ltd.$55.0M26

Take a look at TENX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenax Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TENX

What is the TENX stock price forecast for 2026-2027?

The median 12-month analyst price target for Tenax Therapeutics, Inc. is $5, with estimates ranging from $4 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TENX stock a buy right now?

Of the 10 analysts covering Tenax Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenax Therapeutics, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TENX?

As at 21 Nov 2026, Tenax Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).

Will TENX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $5, and Ticker Nerd's factor model ranks Tenax Therapeutics, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TENX stock forecast for 2030?

No analyst covering Tenax Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TENX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $35 over the next 12 months.

How has TENX stock performed over the past year?

Tenax Therapeutics, Inc. returned -83.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenax Therapeutics, Inc. do?

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction.

Company

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction. Its pipeline includes levosimendan-based programs, as well as other drug candidates aimed at improving outcomes in heart and lung disease. Tenax Therapeutics concentrates on advancing clinical-stage therapies for patients with high unmet medical needs, making it a specialized player in the pharmaceutical market. Headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates as a research-driven company centered on novel treatments for complex cardiopulmonary disorders.

CEO Mr. Christopher T. Giordano · 14 employees · United States · https://www.tenaxthera.com